Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models

Rico, María José; Baglioni, María Virginia; Bondarenko, Maryna; Laluce, Nahuel Cesatti; Rozados, Viviana R.; André, Nicolas; Carré, Manon; Scharovsky, O. Graciela; Márquez, Mauricio Menacho

doi:10.18632/oncotarget.13760

Cited by 64 publications

(60 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Metformin therapy weakens the risk of glioma-initiating cells (48), and inhibits ovarian cancer by increasing sensitivity to cisplatin (49,50), endometrial cancer through changes in Ki-67 proliferation (51-53), and breast cancer (54,55) and non-small cell lung carcinomas (56,57). Laboratory studies on breast cancer have shown that metformin increases the mean life span by 8% and mammary adenocarcinoma latency by 13.2% (P<0.05) in HER2/neu mice (58).…”

Section: Discussionmentioning

confidence: 99%

Aspirin and metformin exhibit antitumor activity in murine breast cancer

Zhao

Wang

et al. 2018

Oncol Rep

View full text Add to dashboard Cite

Abstract. Studies have shown that aspirin and metformin play important roles in chemoprevention and repression of breast cancers, even though the exact mechanism remains unclear. Aspirin is capable of stimulating apoptosis through prostaglandin-dependent or prostaglandin-independent pathways. Metformin inhibits cell growth by enhancing the tumor suppressive function of transforming growth factor (TGF-β).In the present study, we report a new link between aspirin, metformin, TGF-β1 and murine breast cancer inhibition. Specifically, we showed that aspirin and metformin enhanced 4T1 cell apoptosis by inducing secretion of TGF-β1, whereas estradiol weakened the effect.

show abstract

Section: Discussionmentioning

confidence: 99%

Aspirin and metformin exhibit antitumor activity in murine breast cancer

Zhao

Wang

et al. 2018

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…Tumor growth was analyzed by measuring tumor length (a) and width (b) with a caliper, and by calculating tumor volume (V) with Eq. 2 [51]:…”

Section: Repositioning Of Anti-parasitic Drugsmentioning

confidence: 99%

“…Among breast cancer subtypes, triple-negative breast cancer exhibits distinct characteristics, is particularly aggressive and frequently recurrent, and becomes metastatic [3]. These subtypes of tumors account for 15% of all breast cancer types with higher percentages in premenopausal African-American and Hispanic women, and it is associated with very poor prognosis and limited treatment option availability [51]. As shown in Fig.…”

Section: Effect Of Abz and Rbz And Their Cyclodextrin Inclusion Complmentioning

confidence: 99%

Repositioning of Anti-parasitic Drugs in Cyclodextrin Inclusion Complexes for Treatment of Triple-Negative Breast Cancer

Priotti

Baglioni²,

Garcı́a

et al. 2018

AAPS PharmSciTech

View full text Add to dashboard Cite

This e-offprint is for personal use only and shall not be self-archived in electronic repositories. If you wish to self-archive your article, please use the accepted manuscript version for posting on your own website. You may further deposit the accepted manuscript version in any repository, provided it is only made publicly available 12 months after official publication or later and provided acknowledgement is given to the original source of publication and a link is inserted to the published article on Springer's website. The link must be accompanied by the following text: "The final publication is available at link.springer.com". Abstract.Drug repositioning refers to the identification of new therapeutic indications for drugs already approved. Albendazole and ricobendazole have been used as anti-parasitic drugs for many years; their therapeutic action is based on the inhibition of microtubule formation. Therefore, the study of their properties as antitumor compounds and the design of an appropriate formulation for cancer therapy is an interesting issue to investigate. The selected compounds are poorly soluble in water, and consequently, they have low and erratic bioavailability. In order to improve their biopharmaceutics properties, several formulations employing cyclodextrin inclusion complexes were developed. To carefully evaluate the in vitro and in vivo antitumor activity of these drugs and their complexes, several studies were performed on a breast cancer cell line (4T1) and BALB/c mice. In vitro studies showed that albendazole presented improved antitumor activity compared with ricobendazole. Furthermore, albendazole:citrate-β-cyclodextrin complex decreased significantly 4T1 cell growth both in in vitro and in vivo experiments. Thus, new formulations for anti-parasitic drugs could help to reposition them for new therapeutic indications, offering safer and more effective treatments by using a well-known drug.

show abstract

“…Recent studies have shown that β-AR antagonists reduce breast cancer metastasis in vivo [17,104]. Additionally, a combination therapy of propranolol with metformin, a drug used in diabetes mellitus type 2, decreased migration, invasion, and proliferation of five breast cancer cell lines in vitro [125]. A clinical study conducted recently demonstrated that propranolol reduces Ki-67 and Bcl-2 markers in a stage III breast cancer patient.…”

Section: The Bone Marrow Microenvironment As a Target To Treat Breastmentioning

confidence: 99%

Pathological Crosstalk between Metastatic Breast Cancer Cells and the Bone Microenvironment

et al. 2020

View full text Add to dashboard Cite

Bone is the most common metastatic site in breast cancer. Upon arrival to the bone, disseminated tumor cells can undergo a period of dormancy but often eventually grow and hijack the bone microenvironment. The bone marrow microenvironment consists of multiple cell types including the bone cells, adipocytes, endothelial cells, and nerve cells that all have crucial functions in the maintenance of bone homeostasis. Tumor cells severely disturb the tightly controlled cellular and molecular interactions in the bone marrow fueling their own survival and growth. While the role of bone resorbing osteoclasts in breast cancer bone metastases is well established, the function of other bone cells, as well as adipocytes, endothelial cells, and nerve cells is less understood. In this review, we discuss the composition of the physiological bone microenvironment and how the presence of tumor cells influences the microenvironment, creating a pathological crosstalk between the cells. A better understanding of the cellular and molecular events that occur in the metastatic bone microenvironment could facilitate the identification of novel cellular targets to treat this devastating disease.

show abstract

Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models

Cited by 64 publications

References 59 publications

Aspirin and metformin exhibit antitumor activity in murine breast cancer

Aspirin and metformin exhibit antitumor activity in murine breast cancer

Repositioning of Anti-parasitic Drugs in Cyclodextrin Inclusion Complexes for Treatment of Triple-Negative Breast Cancer

Pathological Crosstalk between Metastatic Breast Cancer Cells and the Bone Microenvironment

Contact Info

Product

Resources

About